title: Hepatitis C virus among genitourinary clinic attenders in Scotland: unlinked anonymous testing.
abstract: Our objective is to gauge the prevalence of hepatitis C virus (HCV) antibodies among a population at risk of contracting sexually transmitted infections (STIs) and, thus, the efficiency with which the virus is transmitted sexually. The investigators undertook an unlinked anonymous HCV antibody testing study of residual syphilis serology specimens taken from attenders of genitourinary clinics in Glasgow, Edinburgh and Aberdeen during 1996/97. The results were linked to non-identifying risk information. Anti-HCV prevalences among non-injecting heterosexual men and women, and non-injecting homosexual/bisexual males ranged between 0 and 1.2%; the only exception to this was a 7.7% (4/52) prevalence among homosexual/bisexual males in Aberdeen. The overall anti-HCV prevalence for homosexual/bisexual males was 0.6% (4/668), for heterosexual males 0.8% (32/4135), for heterosexual females 0.3% (10/3035) and for injecting drug users 49% (72/148). Only 3 (all female) of the 46 non-injectors who were antibody positive were non-UK nationals or had lived abroad. HCV antibody positive injectors were less likely to have an acute STI and more likely to know their HCV status than non-injectors; no differences in these parameters were found between positive and negative non-injectors on anonymous HCV antibody testing. Our findings are in keeping with the prevailing view that HCV can be acquired through sexual intercourse but, for most people, the probability of this occurring is extremely low. Interventions to prevent the spread of HCV should be targeted mainly at injecting drug user (IDU) populations.
authors.affiliation: Scottish Centre for Infection and Environmental Health, Glasgow, UK. david.goldberg@scieh.csa.scot.nhs.uk
authors.forename: D
authors.initials: D
authors.lastname: Goldberg
authors.forename: S
authors.initials: S
authors.lastname: Cameron
authors.forename: G
authors.initials: G
authors.lastname: Sharp
authors.forename: S
authors.initials: S
authors.lastname: Burns
authors.forename: G
authors.initials: G
authors.lastname: Scott
authors.forename: P
authors.initials: P
authors.lastname: Molyneaux
authors.forename: A
authors.initials: A
authors.lastname: Scoular
authors.forename: A
authors.initials: A
authors.lastname: Downie
authors.forename: A
authors.initials: A
authors.lastname: Taylor
mesh_terms: D005260:Female; D052776:Female Urogenital Diseases / Q000097:blood / Q000150:complications* / Q000821:virology; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D020010:Heterosexuality; D006716:Homosexuality; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases; D015995:Prevalence; D012307:Risk Factors; D012606:Scotland / Q000453:epidemiology; D016036:Seroepidemiologic Studies; D012749:Sexually Transmitted Diseases / Q000097:blood / Q000150:complications* / Q000821:virology; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000821:virology
chemical_list: D018937:Hepatitis C Antibodies